The abstract is read at the publisher; the summary is JClub's.
Acquired lysines in cancer span 295,411 sites across 20,365 genes and fall on driver hotspots more often than other substitutions (odds ratio 1.68).
- Why it matters: Proteomic studies aim to detect tumor-specific mutant peptides, but reported coverage and error rates may be unreliable for acquired lysines, limiting confidence in mutation-aware proteomics.
- What they did: They reanalyzed 42 proteomic experiments using a mutation-aware database, recovering mutant peptides in 0.63% of 8,470 site-in-cell-line observations, and estimated false-discovery proportion via burden-matched entrapment (4.70% before score filtering).
- The result: Competitive activity-based protein profiling across four cell lines shows ligandability reproduces at the site level, no tested compound descriptor predicts it, and structure predicts it poorly (AUC 0.617), implying detection limits dominate.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.